You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 21 No. 1, July 1969 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  ARTICLES
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (10)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

A New Psychotropic Agent

Solomon H. Snyder, MD; Louis A. Faillace, MD; Herbert Weingartner, PhD

Arch Gen Psychiatry. 1969;21(1):95-101.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

PSYCHEDELIC drugs include a number of compounds of widely varying chemical structures which produce, however, similar subjective effects. The spectrum of the psychedelic syndrome embraces mood changes, alterations in body image, central sympathetic stimulation, changes in thought processes, perceptual distortions, and hallucinations, and is essentially the same for drugs of lysergic acid, tryptamine, and mescaline classes. The possibility that these similar effects result from interaction of these drugs on a common receptor site is supported by the existence of cross-tolerance among psychedelic drugs of different structures1,2 and by similarities of their molecular conformation3 and electronic configuration.4,5

An important therapeutic use of psychedelic drugs has been as facilitators of psychotherapy. In this "psycholytic" usage the facet of drug action applied is its capacity to enhance self-awareness and permit new insight. The failure of this type of therapy . . . [Full Text PDF of this Article]


Author Affiliations



Baltimore

From the Department of Pharmacology and Experimental Therapeuties (Dr. Snyder) and the Department of Psychiatry and Behavioral Sciences (Drs. Snyder, Faillace, and Weingartner), The Johns Hopkins University School of Medicine, Baltimore.


Footnotes



Submitted for publication July 1, 1968.

Reprint requests to the Department of Pharmacology and Experimental Therapeutics, The Johns Hopkins University School of Medicine, 725 N Wolfe St, Baltimore 21205 (Dr. Snyder).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1969 American Medical Association. All Rights Reserved.